66 results about "Prediabetes" patented technology

The invention discloses a data-driven early-diabetic future diabetes-related disease progress risk prediction model and a construction method thereof, and the method comprises the steps: collecting clinical index data, including age, gender, BMI, WHR, HOMA-IR, HDL-C, TG, SBP, DBP, SCR and ALT, of early-diabetic patients in a training and verification queue; using an unsupervised soft clustering method combining dimension reduction based on UMAP, graph clustering and a Gaussian mixture model to identify the phenotypic heterogeneity of the prediabetes mellitus; obtaining the probability of the individual phenotype characteristics, evaluating the association between the probability and the development risk of the future diabetes related diseases in the early stage of diabetes, and constructing a development risk prediction model of the future diabetes related diseases in the early stage of urine diseases; and performing model optimization and robustness verification in the verification queue. According to the method, the heterogeneity of the prediabetes mellitus can be effectively identified, and accurate risk stratification and personalized prevention are realized.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

This invention relates to the intersection of traditional Chinese medicine modernization and intelligent healthcare, specifically falling under the category of pre-chronic disease screening and health management technology. More particularly, it relates to a method for diagnosing and treating pre-type 2 diabetes based on traditional Chinese medicine state theory, along with electronic devices and computer-readable storage media, constructing a complete, human-machine collaborative closed-loop diagnostic and treatment process. This method achieves objective data collection through portable devices using the four diagnostic methods of traditional Chinese medicine, utilizes a multi-algorithm fusion model to accurately identify the "potential pathological state" of pre-T2DM, and intelligently generates personalized intervention prescriptions based on this. Finally, it quantifies the effects and dynamically optimizes the treatment plan through data re-collection and model re-evaluation. This solves the problems of strong subjectivity in traditional Chinese medicine diagnosis and treatment, disconnection from modern technology, and lack of quantitative feedback and continuous adjustment after intervention. It achieves full-cycle, intelligent, and personalized health management for pre-T2DM, from identification and intervention to follow-up management.

Provided is a method and a system for noninvasive measurement of blood viscosity based on oxygen saturation and blood flow rate, which may easily and quickly calculate the blood viscosity by using the method and the system for noninvasive measurement of blood viscosity based on oxygen saturation and blood flow rate, thereby enabling immediate obtaining of the blood viscosity.

The present invention pertains to a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for use in preventing and / or treating a metabolic disorder and / or muscle atrophy. It also pertains to a method of preventing and / or treating a metabolic disorder and / or muscle atrophy in a subject. It furthermore pertains to use of a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for increasing the level of insulin and / or glucagon in the blood of a subject and the present invention also pertains to a non-therapeutic use or method of a) beta-lactoglobulin or b) a nutritional composition comprising BLG. It also pertains to beta-lactoglobulin (BLG) for use in preventing and / or treating diabetes or prediabetes in a subject. It furthermore pertains to a nutritional composition for use in preventing and / or treating diabetes or prediabetes in a subject.

The invention discloses a probiotic agent for relieving prediabetic action and application thereof, and belongs to the technical field of microorganisms. Experiments prove that bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics can relieve the prediabetic stage, which is specifically embodied in reducing weight gain of mice in the prediabetic stage, regulating blood sugar metabolism, improving sugar tolerance and insulin resistance, protecting liver and pancreas tissues, being beneficial to increasing the diversity of intestinal flora, recovering the structure of the intestinal flora, and improving the immunity of the mice in the prediabetic stage. The invention also provides a preparation method of the bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. The bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. And the growth of beneficial bacteria related to metabolic disorder is enriched and regulated. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

An AI-based system (100) designed to assess prediabetes risk in individuals. The system (100) integrates seamlessly with the user devices via rest APIs, ensuring secure communication through https. A data collection module (122) collects raw data forwards the data to standardization and pre-processing modules (124) for preparation. The pre-processed data is transmitted to the server (104) through a network (102) using an API integration module (126) and thereafter forwarded to the input module (112) that authenticates and validates patient data, which is transmitted to the processing module (114) that refines the data, while a prediction module (116) employs a deep learning model with an AUC of 0.87 to evaluate prediabetes risk. A clinical pathway (118) and risk prediction response (120) modules provide personalized protocols, risk status, and clinical recommendations. It (100) complements clinician decision-making, adheres to ISO 13485 standards, and serves as a cost-effective community-based prediabetes risk assessment.

Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and / or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The present invention pertains to a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for use in preventing and / or treating a metabolic disorder and / or muscle atrophy. It also pertains to a method of preventing and / or treating a metabolic disorder and / or muscle atrophy in a subject. It furthermore pertains to use of a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for increasing the level of insulin and / or glucagon in the blood of a subject and the present invention also pertains to a non-therapeutic use or method of a) beta-lactoglobulin orb) a nutritional composition comprising BLG. It also pertains to beta-lactoglobulin (BLG) for use in preventing and / or treating diabetes or prediabetes in a subject. It furthermore pertains to a nutritional composition for use in preventing and / or treating diabetes or prediabetes in a subject.

To provide a technique for predicting the risk of a non-diabetes person developing diabetes or prediabetes in the future.SOLUTION: A diabetes prediction method is provided, comprising an information acquisition step of acquiring subject information of a population consisting of subjects, and a risk score computation step of performing data envelopment analysis to derive risk scores used for assessing the risk of the subjects developing diabetes in the future from the subject information acquired in the information acquisition step.SELECTED DRAWING: Figure 1

The present invention relates to a method for improving glucose homeostasis and / or lowering plasma glucose levels by administering a SIRT6 activator. The present invention also provides a method for treating hyperglycemia, prediabetes, and diabetes, including type I diabetes, type II diabetes, or gestational diabetes, by administering a SIRT6 activator.

The invention relates to a diabetes early subtype recognition and risk prediction system based on continuous blood glucose monitoring. The system comprises a data preprocessing module, a subtype recognition module, a physiological modeling module, a residual prediction module and a fusion prediction module. The data preprocessing module is used for interpolating and standardizing the continuous blood glucose monitoring data; the subtype recognition module is used for extracting a typical daily curve, performing clustering analysis and outputting a metabolic subtype tag; the physiological modeling module is used for constructing and fitting a glucose-insulin kinetic model and outputting personalized physiological parameters; the residual prediction module is used for training the LSTM network and predicting the residual of the dynamic model; and the fusion prediction module is used for dynamically fusing output of the two types of models and generating a final blood glucose prediction result. According to the method, subtypes of the early stage of diabetes can be recognized, a prediction analysis method with high precision and high interpretability can be provided for different subtypes, and individualized dynamic mode recognition and hybrid prediction based on continuous blood glucose monitoring (CGM) data are achieved.

Methods are provided for quantification of lipoprotein subfraction by ion mobility. Also provided herein are methods for diagnosing or prognosing insulin resistance in a patient in need thereof (e.g., diabetic and / or pre-diabetic patients), the method comprising measuring lipoprotein subfraction levels in a patient sample by ion mobility.

The present invention relates to certain SGLT-2 inhibitors for treating, preventing, protecting against and / or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.

The invention relates to a traditional Chinese medicine composition for treating prediabetes and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The composition is prepared from the following raw material medicines: 10 to 20 parts of rhizoma coptidis, 20 to 30 parts of radix astragali seu hedysari, 20 to 30 parts of rhizoma dioscoreae, 12 to 30 parts of rhizoma atractylodis, 10 to 20 parts of herba eupatorii, 15 to 30 parts of roasted rhizoma atractylodis macrocephalae, 15 to 20 parts of poria cocos and 10 to 20 parts of radix ophiopogonis. The traditional Chinese medicine composition disclosed by the invention is prepared according to the traditional Chinese medicine theory of replenishing qi to invigorate the spleen, clearing heat and drying dampness, nourishing yin and promoting the secretion of saliva or body fluid, and aims at regulating glycometabolism, improving the pancreas islet function and controlling abnormal blood glucose; the preparation method comprises the steps of crushing, mixing, wet granulation, drying and the like, and the stability and the curative effect consistency of the granules are ensured. The traditional Chinese medicine composition has the advantages of multiple targets, low side effect, high compliance and the like by systematically optimizing the formula and standardizing the preparation process, is suitable for intervention treatment of the early stage of diabetes, and has good clinical value and industrialization prospect.

The present invention discloses a GLP-1R agonist, a synthesis method thereof and uses thereof, belonging to the field of medicine. The GLP-1R agonist of the present invention has a structure shown in formula (I) and can be used for treating GLP-1R-mediated diseases or disorders in humans, such as treating type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular diseases.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for promoting blood circulation, excreting dampness and reducing blood sugar as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises the following active ingredients in parts by weight: 3-10 parts of prepared radix aconiti lateralis preparata, 5-15 parts of rhizoma zingiberis, 5-15 parts of honey-fried licorice root, 5-15 parts of wine-processed radix cyathulae, 10-30 parts of radix salviae miltiorrhizae, 10-30 parts of radix paeoniae rubra, 10-30 parts of rhizoma alismatis, 5-15 parts of rhizoma coptidis and 10-30 parts of radix puerariae. The traditional Chinese medicine has the effects of tonifying deficiency, dispelling excess, promoting blood circulation, excreting dampness and strengthening the body resistance, not only strengthens healthy qi to treat root causes, but also promotes blood circulation, excretes dampness to treat symptoms, and achieves the effect of treating both symptoms and root causes. Clinical research shows that the traditional Chinese medicine composition can promote blood circulation, excrete dampness and strengthen healthy qi, so that the fasting blood-glucose level of people suffering from prediabetes is reduced, and the aim of effectively treating the prediabetes is achieved.

The invention belongs to the technical field of early diagnosis of prediabetes mellitus, and particularly relates to a prediabetes mellitus exhaled gas biomarker composition as well as an identification method, a screening method, a device, a medium, a program product and a terminal of the prediabetes mellitus exhaled gas biomarker composition. The invention provides a marker screening method for prediabetic exhaled gas, a biomarker composition for prediabetic exhaled gas is screened out, the biomarker composition comprises undecane, 4-ethyl octane, 2, 5-bis (1, 1-dimethyl ethyl)-phenol, 1-methoxy-2-acetone, acetone and tetradecane, healthy groups and prediabetic exhaled gas can be distinguished through an XGBoost model, and the prediabetic exhaled gas can be screened out. The kit is used for early-stage diagnosis of diabetes.

A polymorphic form of a GLP-1R agonist compound (III), a preparation method therefor and a use thereof are provided. Compared with an amorphous form of compound (III), the polymorphic form has higher stability and better processability, and is more suitable for preparing a drug for preventing or treating diseases related to a GLP-1R target and a signaling pathway thereof, such as type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, kidney disease, gout, hyperhematuria, cardiovascular disease, etc.

This invention relates to the field of clinical evaluation technology, specifically a stratified randomized controlled trial method for evaluating the intervention of traditional Chinese medicine compound formulas in prediabetes. The method includes the following steps: constructing stratified codes for subjects based on fasting blood glucose differences; constructing a blood glucose change difference sequence by combining the differences before and after intervention; using a regression function to obtain characteristic inflection points and establish a dose interval mapping relationship; obtaining the peak blood glucose time based on glucose tolerance tests and segmenting the time axis; calculating the slope characteristic parameters of each segment; and classifying and judging the comprehensive parameters and mapping relationship to construct a efficacy grading evaluation index. In this invention, by comparing multiple fasting blood glucose differences with stable parameters to extract fluctuation characteristics, a stratified coding mechanism is constructed to avoid the risk of stratification mismatch in a single test. The intervention difference is extracted and used to introduce piecewise linear regression to calculate the slope and capture the response characteristic inflection points. Combined with standard comparison, the degree of recovery of the body is determined, and the curve shape is transformed into a multi-dimensional efficacy grading index, effectively improving clinical precision.

The present disclosure relates to methods employing polygenic scores for determining and stratifying risk of development of type 2 diabetes mellitus (T2D) in human subjects and related prediabetes conditions such as hyperglycemia.

Described herein are detecting methods for conformational disease, aging and proteinopathies, by measuring the presence of b-isox-precipitates and the levels of b-isox-captured proteins in biofluids of healthy individuals and patients. Research identified additional biomarkers, which made it possible to detect, diagnose or treat, a human disease in a human subject by, with or without adding an isoxazole to an obtained biofluid sample, detecting the biomarker. Use of b-iso and / or biomarkers for diagnosing the disease are made possible.

According to the traditional Chinese medicine compound composition, rhizoma polygonati, radix codonopsis, rhizoma dioscoreae and fried rhizoma atractylodis macrocephalae are used as monarch medicines, and are used for replenishing qi and strengthening the spleen, and earthing up to build the middle energizer, so that transportation and transformation are right; poria cocos, coix seeds and radix fici simplicissimae are used as ministerial drugs, dried orange peel and fructus amomi are used as ministerial drugs, and the effects of dredging and regulating water channels, resolving dampness, enlivening the spleen, and promoting middle-jiao ascending and descending are achieved, so that three- Radix paeoniae alba, radix curcumae, fructus aurantii and radix cyathulae are matched with radix salviae miltiorrhizae as assistant medicines to soften the liver, dispel depression, regulate qi, guide stagnation, promote blood circulation and dredge collaterals, so that wood is prepared without lumbering, and collaterals are dredged without bitter cold; the radix scrophulariae and the radix ophiopogonis are used for nourishing yin, clearing and moistening, and strengthening yin without moistening greasy middle energizer so as to avoid dampness-aiding and spleen-trapping; and honey-fried licorice root and jujube are used as guide medicines to harmonize the medicines, regulate the middle warmer and protect the stomach so as to improve the symptoms of the diabetes mellitus in the early stage.

The invention belongs to the technical field of diabetes risk prediction, and provides a method and system for predicting the diabetes risk of children prediabetic population, and the method comprises the following steps: S1, multi-modal data fusion collection: collecting children clinical data, biochemical indexes, dynamic blood glucose monitoring data and type 1 diabetes specific data; s2, feature engineering and model construction: carrying out feature engineering processing on the collected data, and extracting key indexes; s3, model training: performing risk prediction by using a machine learning model, and outputting a risk level and a confidence coefficient; s4, generating a personalized intervention scheme according to the risk level; according to the method, the accuracy and reliability of prediction are remarkably improved by combining comprehensive analysis of multi-modal data, key indexes can be accurately extracted through feature engineering and model training, risk prediction can be carried out by utilizing a machine learning model, and the development of child prediabetic people into diabetic patients is effectively delayed or prevented.

The invention relates to a composition that can be used, in particular, as a food ingredient, food supplement, or medicinal product for the prevention of the risk of developing type 2 diabetes, said composition comprising a plant extract selected from each of the following plant families: - Fabaceae, - Lauraceae, - Cannabaceae, - Salicaceae. Figure 4

Provided herein are compositions composed of a plurality of minerals and vitamins that provide numerous health benefits and quality of life to subjects in need thereof. Also described herein are kits composed of the compositions described herein with a marine omega 3 fatty acid, coenzyme Q10, or a combination thereof. In one aspect, the compositions described herein can treat a subject diagnosed with prediabetes, type 1 diabetes, type 2 diabetes or insulin uptake. In another aspect, the compositions described herein can increase the performance of athletes by relaxing and dilating blood vessels, thus improve circulation as well as shorten the time of recovery after exercises or games. In another aspect, the compositions described herein can improve the well-being and immune response system. It also improves the human system against bacterial and fungal infections. In another aspect, the compositions described herein can treat myalgic encephalomyelitis in a subject. In another aspect, the compositions described herein can reduce or prevent one or more symptoms of Crohn's disease in a subject. In another aspect, the compositions described herein can enhance one or more physical properties of a subject after exercise.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

This invention discloses a GLP-1R agonist, its synthesis method, and its uses, belonging to the pharmaceutical field. This invention provides a GLP-1R agonist with the structure shown in formula (I), which can be used to treat human GLP-1R-mediated diseases or conditions, such as type 2 diabetes, prediabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatosis, and cardiovascular diseases.

Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.